Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Sotio Biotech Inc.
M.D. Anderson Cancer Center
Eisai Inc.
Dana-Farber Cancer Institute
NeoImmuneTech
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of Pittsburgh
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
Merck Sharp & Dohme LLC
Virginia Commonwealth University
Merck Sharp & Dohme LLC
Mural Oncology, Inc
Genexine, Inc.
City of Hope Medical Center
University of Virginia
Yale University
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Baptist Health South Florida
Washington University School of Medicine
Five Prime Therapeutics, Inc.
Sellas Life Sciences Group
National Cancer Institute (NCI)
University of Miami
ImmunoGen, Inc.
ADC Therapeutics S.A.
Sumitomo Pharma America, Inc.
Eli Lilly and Company
Medical College of Wisconsin
Duke University
Northwestern University
University of Miami
Incyte Corporation
Tesaro, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
University of Washington
Hoosier Cancer Research Network
Translational Research in Oncology
Merck Sharp & Dohme LLC
Cedars-Sinai Medical Center
Big Ten Cancer Research Consortium
Incyte Corporation